Bruker 9.4T/ 20cm BioSpec MR Scanner for Colorado Animal Imaging Shared Resources

用于科罗拉多州动物成像的布鲁克 9.4T/20cm BioSpec MR 扫描仪 共享资源

• 批准号: 9273825
• 负责人: Natalie J. Serkova
• 金额: $ 200万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-03-01 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9273825
• 关键词: 11 year old; Aging; Animals; Area; Award; Biomedical Research; Cancer Biology; Clinical Sciences; Colorado; Contrast Media; Development; Doctor of Philosophy; Elderly; Equipment; Functional Magnetic Resonance Imaging; Funding; Grant; Image; Imagery; Imaging Techniques; Institutes; Magnetic Resonance Imaging; Medical; Metabolic; Metabolism; Minor; Molecular; Molecular Probes; Neurosciences; Phase; Physiology; Principal Investigator; Protocols documentation; RF coil; Research Personnel; Resolution; Resource Sharing; Small Animal Imaging Systems; Technology; The University of Colorado Cancer Center; Time; Translational Research; United States National Institutes of Health; Universities; anatomic imaging; animal imaging; base; cancer imaging; cardiovascular visualization; driving force; high resolution imaging; imaging scientist; improved; instrument; instrumentation; metabolic imaging; microCT; microPET; microPET/CT; microSPECT; molecular imaging; novel; pre-clinical; ranpirnase; single photon emission computed tomography; spectroscopic imaging

PROJECT SUMMARY AND ABSTRACT University of Colorado Animal Imaging Shared Resources (AISR) is applying for funds to purchase a Bruker 9.4 Tesla/ 20 cm BioSpec MRI scanner. The major users will be 18 investigators (with major NIH and DOD funds) from the University of Colorado Anschutz Medical Campus (AMC), with pending request for 5-10% of instrument time per investigator. Several minor users will be requesting an estimated 1-2% of instrument time per user. All users are supported by a total of 21 active and 6 pending R01 grants, several R21, DOD, K-, U- and P-type of awards. The requested scanner will become a part of the Colorado AISR which is substantially supported as a major Institutional Technology Core by the University of Colorado Cancer Center (UCCC, P30 CA046934-25) and the Colorado Clinical and Translational Sciences Institute (CCTSI, UL1TR001082). The AISR was initially funded in 2006, after a successful S10 shared grant instrumentation application (PI: N. Serkova, PhD) was awarded to purchase a Bruker 4.7 T/16 cm PharmaScan, which was the first small animal imaging system in Colorado. Since 2006, state-of-the-art animal scanners, advanced physiology-based imaging protocols and novel contrast agents/ molecular probes have revolutionized pre-clinical biomedical research at the Anschutz Medical Campus, allowing for non-invasive visualization of cancer biology, physiology and metabolism in a living animal. Based on the existing scientific demand and strong institutional commitment to the AISR, the present animal imaging equipment has expanded to include a Xenogen IVIS200, a Siemens Inveon microPET/CT, and a Mediso microSPECT/CT. Since it was established in 2006, the AISR has been utilized by 124 users (with over 45 of them being MRI-users), with an impressive number of federal grants awarded to support imaging-based translational science in Colorado. Three major areas of expertise have emerged: (i) oncologic imaging; (ii) neuroscience; and (iii) molecular imaging, with various established MR protocols utilizing the existing 4.7 Tesla scanner. The eleven-year old 4.7 Tesla PharmaScan provides reliable anatomical images with spatial resolution in the range of 150 microns. However, the major limitations of the PharmaScan, besides its advanced age and soon-to-be discontinued Bruker support, include the low field strength, limited RF coils and hardware capacities (low SNR, limited in-plane resolution) which are prohibitive for high-resolution imaging, spectroscopic imaging, advanced rapid imaging techniques and imaging of new contrast mechanisms. The sensitivity and image quality from the PharmaScan is not sufficient by today's standards. Therefore, the AISR is seeking to expand the existing aging MR technology with a new 9.4 Tesla BioSpec which will be highly desirable for our users in the areas of: (i) high-resolution anatomical imaging (<75 µm); (ii) EPI (fast BOLD and functional MRI); and (iii) metabolic 1H-MRS and spectroscopic imaging. In addition, fast cardiac imaging with phase-array coils are desirable. Some of these limitations can be overcome by use of microCT (improved spatial resolution), microPET/ SPECT(metabolic and molecular imaging), but the addition of high-field MRI is essential for a state-of-the-art AISR. The AISR team has assembled a strong group of NIH funded principal investigators in the areas of neuroscience, oncology and molecular imaging who are the driving force for assembling this application. The major and secondary users will be supported by a team of highly qualified translational imaging scientists, physicists, and chemists in order to form a successful platform for the development and application of high-resolution, functional, molecular and metabolic MR based protocols using the requested 9.4 Tesla Bruker BioSpec.

项目总结和摘要 科罗拉多大学动物成像共享资源（AISR）正在申请资金购买布鲁克 9.4 Tesla/ 20 cm BioSpec MRI扫描仪。主要用户将是18名研究人员（主要的NIH和DOD 资金）从科罗拉多大学安舒茨医学院（AMC），与悬而未决的要求5-10%的 每个研究者的仪器时间。一些小用户将要求估计1-2%的仪器时间 每个用户。所有用户都得到了总共21个活动和6个待定R 01赠款的支持，几个R21，DOD，K-，U- P类奖项。所要求的扫描仪将成为科罗拉多AISR的一部分， 作为主要的机构技术核心，由科罗拉多大学癌症中心（UCCC，P30）提供支持 CA 046934 -25）和科罗拉多临床和转化科学研究所（CCTSI，UL 1 TR 001082）。 AISR最初是在2006年获得资助的，在成功的S10共享赠款仪器应用（PI：N。 Serkova博士）购买了布鲁克4.7 T/16 cm PharmaScan，这是第一台小型动物 成像系统在科罗拉多。自2006年以来，最先进的动物扫描仪，先进的生理基础 成像协议和新型造影剂/分子探针已经彻底改变了临床前生物医学 在安舒茨医学院的研究，允许癌症生物学的非侵入性可视化， 生理学和新陈代谢。基于现有的科学需求和强大的制度 由于对AISR的承诺，目前的动物成像设备已经扩展到包括Xenogen IVIS 200， Siemens Inveon microPET/CT和Mediso microSPECT/CT。自2006年成立以来，AISR 已经被124个用户使用（其中超过45个是MRI用户），其中有大量的联邦用户。 在科罗拉多，授予支持基于成像的转化科学的赠款。三大专业领域 已经出现了：（i）肿瘤学成像;（ii）神经科学;和（iii）分子成像， 使用现有4.7特斯拉扫描仪的MR方案。11岁的4.7特斯拉PharmaScan提供 空间分辨率在150微米范围内的可靠解剖图像。然而，主要局限性 除了其高龄和即将停止的布鲁克支持外， 场强、有限的RF线圈和硬件容量（低SNR、有限的面内分辨率）， 禁止高分辨率成像、光谱成像、先进的快速成像技术和成像 新的对比机制。PharmaScan的灵敏度和图像质量不足， 今天的标准。因此，AISR正在寻求通过新的9.4 Tesla BioSpec将在以下领域为我们的用户所高度期望：（i）高分辨率解剖 成像（<75 µm）;（ii）EPI（快速BOLD和功能MRI）;（iii）代谢1H-MRS和光谱 显像此外，利用相控阵线圈的快速心脏成像是期望的。其中一些限制可能 通过使用microCT（提高空间分辨率）、microPET/ SPECT（代谢和分子 成像），但高场MRI的添加对于最先进的AISR至关重要。AISR团队拥有 召集了一个强大的NIH资助的主要研究人员在神经科学，肿瘤学和 他们是组装这个应用的驱动力。主要和次要用户 将由一个高素质的翻译成像科学家，物理学家和化学家团队提供支持， 为高分辨率、功能性、分子和 使用要求的9.4特斯拉Bruker BioSpec的基于代谢MR的方案。

项目成果

A novel preclinical model of craniospinal irradiation in pediatric diffuse midline glioma demonstrates decreased metastatic disease.

• DOI: 10.3389/fonc.2023.1105395
• 发表时间: 2023
• 期刊: Frontiers in oncology
• 影响因子: 4.7